Auspherix is an early-stage anti-infectives company offering new hope in the battle against antibiotic resistant bacteria.
By developing a new class of antibiotics the company will strengthen the existing arsenal of antibacterial treatments.
Auspherix’ pre-clinical R&D programmes are based on its discovery of antibacterials with a unique profile. These proprietary compounds have demonstrated activity against a broad range of important multidrug resistant (MDR) Gram-negative and Gram-positive bacterial strains.
Auspherix intends to develop and license these novel antibiotic drug candidate molecules to pharmaceutical companies with expertise in the anti-infective space.